| | | |   | | | | By Angus Chen AP/Business Wire A growing body of evidence is beginning to shatter the idea that “synergy” in drug combinations should be a high priority in cancer research. Read More | | By Damian Garde and Meg Tirrell and Adam Feuerstein We talk to Oppenheimer analyst Jared Holz about why the world has soured on the biotech sector and what it means for the future of medicine. Read More | | By Kathryn Macapagal Justin Sullivan/Getty Images Recent changes in how health care providers should think about PrEP and who it is for have the potential to transform the HIV epidemic. Read More | | Sponsor content by STAT TRIALS PULSE STAT Trials Pulse redefines clinical trials intelligence with a new tool powered by AI and STAT's biotech team STAT and Applied XL have partnered to develop a new clinical trials intelligence platform, STAT Trials Pulse. Combining machine learning and feedback from STAT's trusted newsroom, the platform allows you to monitor the clinical trials landscape and surface critical insights and trends more easily than ever before. Learn more at statnews.com/trials-pulse, or skip the details and start your four-week free trial at trials.appliedxl.com. | |
No comments